University of Michigan | Strategic Alliance Partners

Angel Qin, MD, contextualizes the non–small cell lung cancer ADAURA trial, in which patients with EGFR-mutated non–small cell lung cancer who received adjuvant therapy with osimertinib achieved a 5-year overall survival rate of 85% vs 73% in those who received placebo.

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Lori J. Pierce, MD harbored a love for science and a general desire to know things, and she was not shy about asking questions. She displayed a gift for math early in life, a trait she and her older sister, Karen, both inherited from their father, Melvin H. Pierce.

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

The combination of ModraDoc006—a novel, oral tablet formulation of docetaxel—and ritonavir produced comparable response rates and radiographic progression-free survival to that achieved with intravenous docetaxel in patients with metastatic castration-resistant prostate cancer.

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Michelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer.

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Treatment selection and sequencing in genitourinary cancers, such as metastatic bladder cancer and metastatic renal cell carcinoma, have become more complicated and require nuanced decision making.

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.